Tekla Life Sciences Investors

HQLNYSEFinancial Services● Active

$16.71

$-0.22(-1.27%)

Market Cap$507965640

P/E Ratio—

52W High$18.46

52W Low$12.34

Avg Volume105K

Open$17.07

Beta0.73

Net Income Financials Revenue

Tekla Life Sciences Investors (HQL) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

HQL · net income · updated Jun 8, 2026

Core profitability metrics

HQL · net income · margin · TTM · CAGR

Net income was $85.6M for FY2025 (fiscal year ending 2025-09-30), up 0.3% year-over-year. Net profit margin was 99.1%. Based on available data, Tekla Life Sciences Investors has been profitable since at least 2011.

FY2025 Net Income$85.6M▲ +0.3% YoY

Trailing 12M (TTM)$170.9Mtrailing 4 quarters sum

Net Profit Margin99.1%$85.6M ÷ $86.4M

YoY Change+0.3%—

5-Year CAGR-7.0%FY2020 → FY2025

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2011

▸ FMP /income-statement · Annual · HQL net income history · HQL profit margin

Annual net income data

HQL · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025$85.6M▲ +0.3%99.1%$86.4M

FY2024$85.3M▲ +281.6%98.4%$86.7M

FY2023$22.4M▲ +121.4%56.8%$39.4M

FY2022Loss−$104.6M▼ 262.1%-328.3%$31.9M

FY2021$64.5M▼ 47.6%143.3%$45.0M

Net income vs peers (Financial Services)

HQL vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Tekla Life Sciences InvestorsYOU

HQL

$85.6M+0.3%99.1%

Berkshire Hathaway Inc.

BRK-A

$66.97B-24.8%18.0%

100%

Berkshire Hathaway Inc.

Mastercard Incorporated

$14.97B+16.3%45.6%

22%

Financial Services · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Tekla Life Sciences Investors (HQL) reported net income of $85.6M for FY2025 (fiscal year ending 2025-09-30), up 0.3% year-over-year. The net profit margin was 99.1% — meaning the company kept $0.99 of every dollar of revenue as profit.

Based on available data, Tekla Life Sciences Investors has been profitable since at least 2011. Net income reached a peak of $123.1M in FY2020. Data available for 15 fiscal years.

Tekla Life Sciences Investors's net profit margin was 99.1% for FY2025, based on the latest annual results.

Investors sometimes search for "Tekla Life Sciences Investors net worth" — the company's market capitalization is a separate figure from HQL net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

HQL net income · 5 questions

Tekla Life Sciences Investors is profitable. The company reported net income of $85.6M for FY2025, a net profit margin of 99.1%. Net income was up 0.3% year-over-year. Based on available data, Tekla Life Sciences Investors has been profitable since at least 2011.

is HQL profitabledoes HQL make a profitHQL profitabilityHQL profitable company

▸ Source: FMP /income-statement · GAAP · Tekla Life Sciences Investors · Tekla Life Sciences Investors SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026